ReviewMedical oncology (Northwood, London, England)2025
Wearable nanopatch platforms for real-time miRNA sensing and editing: a vision for next-generation cancer management.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy is undergoing an evolution where on-the-spot, adaptable, and fully personalized treatment will soon be in vogue. Central to this progress are microRNAs (miRNAs), which serve as key regulators in cancer biology. Their altered expression profiles not only provide valuable biomarkers enabling early cancer detection but also offer dynamic molecular targets for therapeutic intervention. miRNAs are key regulators frequently used as cancer biomarkers, enabling early detection and timely intervention. Recent advances in wearable biosensing technologies have ushered in innovative platforms such as smart bandages, flexible electronic tattoos, and microneedle arrays that can monitor molecular biomarkers, including miRNAs, directly from interstitial fluid in a minimally invasive way. Emerging therapeutic applications now include wearable miRNA-editing patches that hold promise to correct dysregulated miRNAs at the disease site. This approach moves beyond static, standard treatments toward dynamic and adaptive cancer therapies tailored in real time. This review discusses the scientific basis of miRNA roles in cancer, recent technological breakthroughs in wearable biosensing and gene editing, and key translational challenges-such as biocompatibility, targeted delivery, and regulatory approvals-that must be addressed to realize the potential of truly personalized next-generation cancer therapy platforms.
Indexed as
Identifiers
41247604What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.